Charles Riv­er Lab­o­ra­to­ries snaps up Cog­nate for a cool $875M, looks to ex­pand cell and gene ther­a­py CD­MO foothold

With the cell and gene ther­a­py space as hot as ever, big-name CD­MO Charles Riv­er Lab­o­ra­to­ries is look­ing to carve out a big piece of the pie. To get there, it’s snap­ping up a Mem­phis-based spe­cial­ist in the space.

Charles Riv­er Lab­o­ra­to­ries an­nounced Wednes­day that it ac­quired Cog­nate BioSer­vices, a cell and gene ther­a­py spe­cial­ist with op­er­a­tions in the US and EU.

The move will build Charles Riv­er’s foothold in the cell and gene in­dus­try as it ab­sorbs Cog­nate’s tech, which is al­so used in cel­lu­lar im­munother­a­py and im­muno-on­col­o­gy, re­gen­er­a­tive med­i­cine, and ad­vanced cell ther­a­py ther­a­peu­tics. Not to men­tion the com­pa­ny’s 500+ em­ploy­ees, which will join some 17,000+ Charles Riv­er work­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.